The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

World Journal of Surgical Oncology

Senol Coskun²  Huseyin Abali¹  Hakan Bozcuk² 

[1]Adana Başkent Hospital, Dept. of Medical Oncology, Adana, Turkey

[2]Akdeniz University Hospital, Dept. of Medical Oncology, Antalya, Turkey

关键词: Non-small-cell lung cancer;    Neoadjuvant chemotherapy;    Mortality;    Metaregression;    Meta-analysis;   

Others  :  827419
DOI  :  10.1186/1477-7819-10-161

 received in 2012-03-18, accepted in 2012-07-16,  发布年份 2012

【 摘 要 】

Background

Although neoadjuvant chemotherapy (NCT) is widely used, it is not clear which subgroup of locally advanced non-small-cell lung cancer (NSCLC) patients should be treated with this approach, and if a particular benefit associated with NCT exists. In this study, we aimed to investigate the potential correlates of benefit from NCT in patients with NSCLC.

Methods

All randomized clinical trials (RCTs) utilizing a NCT arm (without radiotherapy) versus a control arm before surgery were included for metaregression analysis. All regression analyses were weighed for trial size. Separate analyses were conducted for trials recruiting patients with different stages of disease. Previously published measures of treatment efficacy were used for the purpose of this study, regardless of being published in full text or abstract form.

Results

A total of 14 RCTs, consisting of 3,615 patients, were selected. Histology, stage, various characteristics of the NCT protocol, and different trial features including trial quality score were not associated with the benefit of NCT. However, in trials of stage 3 disease only, there was a greater benefit in terms of reduction in mortality from NCT, if protocols with three chemotherapeutics were used (B = −0.18, t = −5.25, P = 0.006).

Conclusions

We think that patients with stage 3 NSCLC are served better with NCT before surgery if protocols with three chemotherapy agents or equally effective combinations are used. In addition, the effect of neoadjuvant chemotherapy is consistent with regard to disease and patient characteristics. This finding should be tested in future RCTs or individual patient data meta-analyses.

【 授权许可】

   
2012 Bozcuk et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]SEER: SEER Stat Fact Sheets: Lung and Bronchus. http://seer.cancer.gov/statfacts/html/lungb.html webcite
• [2]NCCN: NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, version 3 2011. http://www.nccn.com webcite
• [3]Crinò L, Weder W, van Meerbeeck J, Felip E, on behalf of the ESMO Guidelines Working Group: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):103-115.
• [4]Burdett S, Stewart L, Rydzewska L: A systematic review and meta-analysis of the literature: chemotherapy and surgery verus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006, 1:611-621.
• [5]Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, Sculier JP: Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a metaanalysis of the literature. Lung Cancer 2005, 49:13-23.
• [6]Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck J, Nankivell M, Parmar M, Pugh C, Stephens R: Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007, 369:1929-1937.
• [7]Song WA, Zhou NK, Wang W, Chu XY, Liang CY, Tian XD, Guo JT, Liu X, Liu Y, Dai WM: Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer. An updated meta-analysis of 13 randomized control trials. 5th edition. 2010, 510-516. [J Thorac Oncol]
• [8]Burdett S, Rydzewska LH, Tierney JF, Pignon JP: Pre-operative chemotherapy improves survival and reduces recurrence in operable non-small cell lung cancer: preliminary results of a systematic review and meta-analysis of individual patient data from 13 randomised trials. J Thor Oncol 2011, 6(Suppl 2):374-375.
• [9]Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
• [10]Dautzenberg B, Benichou J, Allard P, Lebeau B, Coetmeur D, Brechot JM, Postal MJ, Chastang C: Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic nonsmall cell carcinoma. Results from a randomized phase II trial. Cancer 1990, 65:2435-2441.
• [11]Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994, 330:153-158.
• [12]Rosell R, Gómez-Codina J, Camps C, Javier Sánchez J, Maestre J, Padilla J, Cantó A, Abad A, Roig J: Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999, 26:7-14.
• [13]Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M, Neely Atkinson E, Hong WK: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994, 86:673-680.
• [14]Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998, 21:1-6.
• [15]Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarié E, Gouva S, Paillot N, Bréchot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchâtre M, Coëtmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C, French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002, 20:247-253.
• [16]Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, Kato H, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003, 125:254-260.
• [17]Sorensen HR, Ravn J, Hansen O, Palshof T, Rytter C, Mattson K, Ladegaard L, Pilegaard H, Aaseboe U: Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3. J Clin Oncol 2005, 23:LAB7146.
• [18]Pisters K, Vallieres E, Bunn P, Crowley J, Ginsberg R, Ellis P, Meyers B, Marks R, Treat J, Gandara D, Southwest Oncology Group: A phase III trial of surgery alone or surgery plus pre-operative (pre-op) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 2006, 24:LBA7012.
• [19]Pisters K, Vallieres E, Bunn PA, Crowley J, Chansky K, Ginsberg R, Gandara DR, Southwest Oncology Group: Southwest Oncology Group. S9900: Surgery alone or surgery plus induction (ing) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial. J Clin Oncol 2007, 25:LAB7520.
• [20]Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski T, Maiorino A, Hetzel M, Visseren-Grul C, Torri V: A phase III randomized study of surgery alone or surgery plus preoperative gemcitabinecisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of Ch.E.S.T. J Clin Oncol 2008, 26:LAB7508.
• [21]Zhou Q, Liu L, Li L, Che G, Yang J, Zhao Y, Chen J, Wang Y, Qin J, Hou M, Gong Y, Lu W, Li Z: A randomized clinical trial of preoperative neoadjuvant chemotherapy followed by surgery in the treatment of stage III non-small cell lung cancer [in Chinese]. Chin J Lung Cancer 2001, 4:251-256.
• [22]Liao ML, Zhou YZ, Ding JA, Ni GX, Zhao JM, Chen WH, Han BH, Shen J, Bai H, Chen ZW, Ji H, Wang HM, Zhou Z: The study of peri-operative chemotherapy in stage I-IIIa NSCLC [in Chinese]. Zhonghua Yi Xue Za Zhi 2003, 83:962-966.
• [23]Zhou Q, Liu L, Li L, Che G, Yang J, Zhao Y, Chen J, Wang Y, Qin J, Hou M, Gong Y, Lu W, Li Z: A randomized clinical trial of preoperative neoadjuvant chemotherapy in the treatment of stage III non-small cell lung cancer [in Chinese]. J Clin Oncol China 2004, 31:611-613.
• [24]Li Q, Song YH, Zheng ZY, et al.: Clinical evaluation of preoperative short course chemotherapy in treatment of stage III non-small cell lung cancer. Chin J Cancer Prev Treat 2005, 10:505-507.
• [25]Scagliotti GV, on behalf of Ch.E.S.T. Investigators: Preliminary results of Ch.E.S.T.: a phase III study of surgery alone or surgery plus pre-operative gemcitabine-cisplatin in clinical early stages non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006, 23:LBA7023.
• [26]Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B, Spanish Lung Cancer Group: Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small cell lung cancer. J Clin Oncol 2010, 28:3138-3145.
• [27]Esteban E, de Sande JL, Villanueva N, Corral N, Muñiz I, Vieitez JM, Fra J, Fernández Y, Estrada E, Fernandez JL, Luque M, Jimenez P, Mareque B, Capellan M, Buesa JM, Lacave AJ: Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study. Lung Cancer 2007, 55:173-180.
• [28]Schallier D, Neyns B, Fontaine C, Steene JV, De Mey J, Meysman M, De Grève J: A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC). Lung Cancer 2007, 56:247-254.
• [29]Craig R, Coleman O, Michael J: Schell randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808-5815.
• [30]Simon GR, Ismail-Khan R, Bepler G: Nuclear excision repair-based personalized therapy for nonsmall cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 2007, 39:1318-1328.
• [31]Bozcuk H, Artac M, Ozdogan M: Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. J BUON 2010, 15:43-50.
• [32]Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F: Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer systematic review and indirect comparison meta-analysis of randomized trials. Thorac Oncol 2009, 4:1380-1388.